https://www.onhealthcare.tech/p/how-a-split-fda-advisory-panel-voted-8b8Thoughts on Healthcare Markets & Technologyen2026-07-26T02:54:13+00:00How a Split FDA Advisory Panel Voted Six of Seven Peptides Onto the 503A Compounding List Over Its Own Scientists, Rejecting Only Emideltide, and What That Actually Changes for the Markethttps://www.onhealthcare.tech/p/how-a-split-fda-advisory-panel-votedThoughts on Healthcare Markets & Technologyen2026-07-26T02:48:44+00:00How a Split FDA Advisory Panel Voted Six of Seven Peptides Onto the 503A Compounding List Over Its Own Scientists, Rejecting Only Emideltide, and What That Actually Changes for the Markethttps://www.onhealthcare.tech/p/sometimes-interoperability-is-justThoughts on Healthcare Markets & Technologyen2026-07-24T14:15:08+00:00Sometimes Interoperability Is Just a Modifier: CMS’s CY 2027 Imaging Site-Neutral Cut, the Hospital Machine-Readable File, 835 Allowed-Amount Percentiles, and the Contract-Semantics Price RFIhttps://www.onhealthcare.tech/p/part-ii-sometimes-interoperabilityThoughts on Healthcare Markets & Technologyen2026-07-24T14:07:07+00:00Part II: Sometimes Interoperability Is Just a Modifier: CMS’s CY 2027 Imaging Site-Neutral Cut, the Hospital Machine-Readable File, 835 Allowed-Amount Percentiles, and the Contract-Semantics Pricehttps://www.onhealthcare.tech/p/part-i-sometimes-interoperabilityThoughts on Healthcare Markets & Technologyen2026-07-24T14:05:22+00:00Part I: Sometimes Interoperability Is Just a Modifier: CMS’s CY 2027 Imaging Site-Neutral Cut, the Hospital Machine-Readable File, 835 Allowed-Amount Percentiles, and the Contract-Semantics Price